NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $10,143,000 | +142.4% | 95,451 | +36.2% | 0.43% | +96.4% |
| Q4 2017 | $4,184,000 | -58.8% | 70,062 | -83.4% | 0.22% | -57.0% |
| Q3 2017 | $10,154,000 | +25.2% | 423,100 | +2.0% | 0.51% | +16.6% |
| Q2 2017 | $8,109,000 | +200.0% | 414,800 | +260.2% | 0.44% | +227.6% |
| Q1 2017 | $2,703,000 | +6.6% | 115,150 | -44.3% | 0.13% | -20.2% |
| Q4 2016 | $2,535,000 | +28.0% | 206,600 | +14.3% | 0.17% | -1.2% |
| Q3 2015 | $1,981,000 | +18.3% | 180,716 | +24.6% | 0.17% | -0.6% |
| Q2 2013 | $1,675,000 | – | 145,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |